Gallistl S, Cvirn G, Leschnik B, Muntean W
Ludwig Boltzmann Research Institute for Pediatric Hemostasis and Thrombosis, University of Graz, Austria.
Blood Coagul Fibrinolysis. 2002 Oct;13(7):653-5. doi: 10.1097/00001721-200210000-00012.
Activated prothrombin complex concentrates (APCCs) are effective in the therapy of bleeding episodes in hemophilic patients with inhibitors. We investigated the respective roles of factor II, factor VII, factor IX, and factor X in the procoagulant activity of the APCC FEIBA. Factor II, factor VII, factor IX, and factor X were reduced in platelet-poor plasma, and the thrombin potential (TP) was determined using a chromogenic substrate in the absence or presence of FEIBA. Reduction of factor II resulted in a significant decrease of the TP without influencing the lag phase until the onset of thrombin generation. The reduction of factor VII showed no effect on the TP, but resulted in a prolongation of the lag phase. Changes of factor IX or factor X concentrations showed neither an effect on the TP nor on lag phases. Our study demonstrates that thrombin generation in the presence of FEIBA mainly depends on prothrombin.
活化凝血酶原复合物浓缩剂（APCCs）在治疗有抑制剂的血友病患者出血发作方面有效。我们研究了凝血因子II、凝血因子VII、凝血因子IX和凝血因子X在APCC FEIBA促凝活性中的各自作用。在乏血小板血浆中降低凝血因子II、凝血因子VII、凝血因子IX和凝血因子X，并在不存在或存在FEIBA的情况下使用显色底物测定凝血酶潜力（TP）。凝血因子II的降低导致TP显著降低，而在凝血酶生成开始前不影响延迟期。凝血因子VII的降低对TP没有影响，但导致延迟期延长。凝血因子IX或凝血因子X浓度的变化对TP和延迟期均无影响。我们的研究表明，在FEIBA存在的情况下，凝血酶生成主要取决于凝血酶原。
